Catalyst Event

Eli Lilly and Co (LLY) · Other

From Akros U.S. Large Cap 500 Protective Allocation Monthly Index (A500PAM)

6/8/2026, 12:00:00 AM

OtherSentiment: Positive

Announced positive results from Phase 3 trials for its next-generation obesity drug, retatrutide, showing substantial weight loss and improvements in related conditions like sleep apnea and knee osteoarthritis pain, causing the stock to rise.

Korean Translation

차세대 비만 치료제 레타트루타이드(retatrutide)의 3상 임상시험에서 상당한 체중 감소 및 수면 무호흡증, 무릎 골관절염 통증 등 관련 질환 개선 효과를 확인한 긍정적인 결과를 발표함. 이 소식으로 주가가 상승함.

Related Recent Events

View Full Timeline